Ebola Hemorrhagic Fever
6
0
0
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 6 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 3 completed trials
Clinical Trials (6)
Clinical Validation of Isothermal Nucleic Acid Amplification Bioassays Modules - DRC
Clinical Validation of Isothermal Nucleic Acid Amplification Bioassays Modules - GUINEA
Open Study of the Duration of Immunity After Vaccination With GamEvac-Combi
Experimental Vaccine for Prevention of Ebola Virus Infection
A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult Volunteers
Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for Ebola Virus